Global Clinical Trial Biodeposit and Archiving Solutions Market Overview to 2028


DUBLIN, September 30, 2021 / PRNewswire / – The Clinical Trial Biodeposit and Archiving Solutions Market Size, Share and Trend Analysis Report by Department (Biodeposit Services, Archiving Solution Services), by Product (Clinical, Preclinical ), by phase and segment forecast, 2021-2028 ” report was added to offer.

Research and Markets logo

Global Clinical Trial Archiving and Biodepositing Solutions Market Size is Expected to Reach $ 6.0 billion by 2028, according to a new report from the publisher. It is expected to increase at a CAGR of 8.2% from 2021 to 2028. This is largely due to the growing importance of managing biological samples in clinical trials and the desire to streamline data collection and reporting.

Biodepots have entered the era of Big Data, which requires new computer technologies, artificial intelligence (AI) techniques, and machine learning and deep learning tools and algorithms. These features contribute to the paradigm shift towards data-driven science through better quality biobank data. Cloud storage and other new data storage technologies help solve the problem of limited local storage capacity.

New IT solutions such as the sample / data negotiator and locator, which are part of the BBMRI-ERIC infrastructure, facilitate the discovery of samples and data that meet specific criteria. This new level of biobank activity contributes to basic research, translational research and treatment of a wide range of human disorders, including cancer, rare cardiovascular diseases, diabetes and neurodegenerative diseases.

In addition, the COVID-19 pandemic has created opportunities for local actors. To strengthen their market presence, key companies are adopting various plans and policies to gain greater market share. The important step that key players can take on is to partner with relevant third-party vendors. This can be achieved through appropriate communication and adjustments to the frequency and volume of bio-deposition and clinical trial archival solutions.

Highlights of the Clinical Trial Biodeposit and Archiving Solutions Market Report

  • By service, biodepot services dominated the market with a revenue share of 67.2% in 2020. This can be attributed to the increase in R&D of advanced therapies such as personalized medicine and the requirement for practical of high quality biodepot for collection, treatment, testing. , and sample storage

  • In terms of phase, the phase III segment dominated the market with a revenue share of 52.1% in 2020

  • Based on the product, clinical products held the largest share of 63.1% in 2020. This can be attributed to the fact that most clinical trial protocols largely depend on the analysis of biological samples for meet study evaluation criteria.

  • Asia Pacific is expected to register the fastest growth rate of 15.3% during the forecast period. The relocation of clinical trial sites from western regions, such as Europe and North America, To Asia Pacific is a major driver of the regional market

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Biodeposit and Archiving Solutions Market: Variables, Trends and Scope
3.1 Market Segmentation and Scope
3.2 Market dynamics
3.2.1 Market Drivers Analysis Growing number of pharmaceutical and biotechnology companies Increasing variation and prevalence of diseases Increase R&D investments Growth of the CRO market
3.2.2 Analysis of market restrictions Regulation of the development of new drugs Increasing cost of clinical trials
3.3 Mapping of penetration and growth prospects
3.4 Impact of COVID-19 on the market
3.5 Analysis of major transactions and strategic alliances
3.6 Biodeposit and clinical trial archiving solutions: market analysis tools
3.6.1 Industry Analysis – Porter’s
3.6.2 PESTEL analysis

Chapter 4 Clinical Trial Biodeposit and Archiving Solutions Market: Service Segment Analysis
4.1 Clinical Trial Biodeposit and Archiving Solutions Market: Services Market Share Analysis, 2020 and 2028
4.2 Bio-depot services
4.2.1 Bio-Depot Services Market, 2016-2028 (USD Million)
4.3 Archiving solution services
4.3.1 Archiving Solutions Services Market, 2016-2028 (USD Million)

Chapter 5 Clinical Trial Biodeposit and Archiving Solutions Market: Product Segment Analysis
5.1 Clinical Trial Biodeposit and Archiving Solutions Market: Product Market Share Analysis, 2020 and 2028
5.2 Preclinical products
5.2.1 Preclinical Products Market, 2016-2028 (USD Million)
5.3 Clinical products
5.3.1 Clinical Products Market, 2016-2028 (USD Million)

Chapter 6 Clinical Trial Biodeposit and Archiving Solutions Market: Phase Segment Analysis
6.1 Clinical Trial Biodeposit and Archival Solutions: Phased Market Share Analysis, 2020 and 2028
6.2 Phase I
6.2.1 Phase I Market, 2016-2028 (USD Million)
6.3 Phase II
6.3.1 Phase II Market, 2016-2028 (USD Million)
6.4 Phase III
6.4.1 Phase III Market, 2016-2028 (USD Million)
6.5 Phase IV
6.5.1 Phase IV Market, 2016-2028 (USD Million)

Chapter 7 Clinical Trial Biodeposit and Archiving Solutions Market: Regional Analysis

Chapter 8 Company Profiles
8.1 Brooks Life Sciences
8.1.1 Company overview
8.1.2 Benchmarking of services
8.1.3 Financial performance
8.1.4 Strategic initiatives
8.2 Pathéon
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Benchmarking of services
8.2.4 Strategic initiatives
8.3 Precision for Medicine, Inc.
8.3.1 Company overview
8.3.2 Benchmarking of services
8.3.3 Strategic initiatives
8.4 Medical space
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Benchmarking of services
8.5 LabCorp Drug Development
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Benchmarking of services
8.6 ATCC
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Benchmarking of services
8.7 T2 solutions
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Benchmarking of services
8.7.4 Strategic initiatives
8.8 Labconnect
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Benchmarking of services
8.9 Charles River Laboratories
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Benchmarking of services
8.9.4 Strategic initiatives
8.9.5 Strategic initiatives
8.10 Cell & Co
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Benchmarking of services
8.10.4 Strategic initiatives
8.10.5 Strategic initiatives

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716



Show original content:–archiving-solutions-global-market-to-2028—featuring-patheon-medpace-and-atcc -among-others-301389129.html

SOURCE Research and Markets

Leave A Reply

Your email address will not be published.